TScan Therapeutics, Inc. (TCRX)
| Market Cap | 13.77M -89.2% |
| Revenue (ttm) | 7.11M +2.2% |
| Net Income | -117.71M |
| EPS | -1.74 |
| Shares Out | 67.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 262,783 |
| Open | 0.2206 |
| Previous Close | 0.2162 |
| Day's Range | 0.2015 - 0.2270 |
| 52-Week Range | 0.2014 - 2.4290 |
| Beta | 1.14 |
| Analysts | Hold |
| Price Target | 1.00 (+392.13%) |
| Est. Earnings | Nov 11, 2026 |
About TCRX
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It ... [Read more]
Financial Performance
In 2025, TScan Therapeutics's revenue was $10.33 million, an increase of 266.65% compared to the previous year's $2.82 million. Losses were -$129.77 million, 1.78% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TCRX stock is "Hold." The 12-month stock price target is $1.0, which is an increase of 392.13% from the latest price.
News
TScan Therapeutics Proxy statement: Proxy filing
TScan Therapeutics filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Andres Maldonado downgraded TScan Therapeutics (TCRX) to Neutral from Buy with a price target of $1, down from $7. The company announced a restructuring to focus on…
TScan downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital analyst Sam Slutsky downgraded TScan Therapeutics (TCRX) to Market Perform from Outperform.
Needham downgrades TScan Therapeutics as company reprioritizes
As previously reported, Needham downgraded TScan Therapeutics (TCRX) to Hold from Buy and removed the firm’s prior price target after the company announced a strategic reorganization that will see it…
TScan Therapeutics downgraded to Hold from Buy at Needham
Needham downgraded TScan Therapeutics (TCRX) to Hold from Buy.
TScan Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded TScan Therapeutics (TCRX) to Neutral from Outperform with a price target of $1, down from $5, after a strategic reorganization that pauses further enrollment in the Phase 3…
TScan Therapeutics Transcript: Study update
Two in vivo TCR therapies for solid tumors have advanced to IND-enabling activities, with preclinical data and regulatory updates expected in Q1 2027 and a phase I trial planned for Q4 2027. The heme malignancy program showed strong early results but is paused pending partnerships, while the autoimmune program is also on hold. Financial runway now extends to Q4 2027.
TScan Therapeutics Press release: Study update
TScan Therapeutics issued a press release on September 2, 2026, disclosing material business information to investors.
TScan Therapeutics Slides: Study update
TScan Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
TScan Therapeutics to strategically reorganize, reduce workforce by 75%
TScan Therapeutics (TCRX) announced it is strategically reorganizing to prioritize its in vivo solid tumor program, advancing two product candidates to IND-enabling studies. The company also announced...
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA...
TScan Therapeutics reports Q2 EPS (23c), consensus (20c)
Reports Q2 revenue $1.05M, consensus $2.5M. “This is a transformative time for TScan with our first pivotal study now enrolling at major transplant centers across the U.S.,” said Gavin MacBeath,…
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturin...
TScan Therapeutics Earnings release: Q2 2026
TScan Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
TScan Therapeutics Quarterly report: Q2 2026
TScan Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
TScan Therapeutics doses first patient in ALLOHA-2 trial
TScan Therapeutics (TCRX) announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2 trial. The patient, who was enrolled in June, has now received…
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
The lead T cell therapy program is advancing to phase III for post-transplant relapse prevention in heme malignancies, with strong early efficacy signals and improved manufacturing. The pivotal trial is designed for broad accessibility and regulatory rigor, with regular data updates and financial strategies in place to bridge to top-line results.
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Transcript: KOL event
Updated phase I data show TSC-101 achieves high rates of complete donor chimerism and strong safety in difficult-to-treat post-transplant AML/MDS patients. The new manufacturing process improves efficiency, and the phase III pivotal trial is launching with broad market expansion plans.
TScan Therapeutics Press release: KOL event
TScan Therapeutics issued a press release on June 22, 2026, disclosing material business information to investors.
TScan Therapeutics Slides: KOL event
TScan Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 22, 2026.
TScan Therapeutics presents data from Cohort C of ALLOHA trial
TScan Therapeutics (TCRX) presented data from Cohort C of the ongoing ALLOHA Phase 1 study, evaluating TSC-101 generated with the commercial-ready manufacturing process, in patients with heme malignan...
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101
TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing
Cellares and TScan Therapeutics (TCRX) announced an agreement to evaluate automated clinical manufacturing of TSC-101, TScan’s lead TCR-T therapy candidate for patients with acute myeloid leukemia (AM...